Litcius/Paper detail

Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

Thomas Harder, Judith Koch, Sabine Vygen-Bonnet, Wiebe Külper‐Schiek, Antonia Pilic, Sarah Reda, Stefan Scholz, Ole Wichmann

2021Eurosurveillance135 citationsDOIOpen Access PDF

Abstract

Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80-90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.

Topics & Concepts

InterimAsymptomaticMedicineCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Transmission (telecommunications)2019-20 coronavirus outbreakVirologyImmunologyIntensive care medicineInternal medicineDiseaseInfectious disease (medical specialty)OutbreakArchaeologyElectrical engineeringHistoryEngineeringSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies
Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021 | Litcius